Clinical trial
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin…
NCT00493636 · Accelerated Community Oncology Research Network, Other · Completed
Key facts
| NCT number | NCT00493636 |
|---|---|
| Title | 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy |
| Official title | A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy |
| Lead sponsor | Accelerated Community Oncology Research Network, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Sorafenib, Placebo, Capecitabine |
| Enrollment | 160 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Nov 1, 2012 |
| First posted | Jun 28, 2007 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: